Empagliflozin, the diabetes drug can improve the cardiac structure among patients with type 2 diabetes along with heart disease, according to a study led by St. Michael's Hospital researchers.
This study was presented at a prestigious late-breaker session at the American Heart Association meeting in Chicago.
‘Patients with type 2 diabetes and heart disease could be benefited with empagliflozin drug, which helps provide various cardiac benefits.’
"Empagliflozin is used to reduce glucose in diabetes patients, but it also has profound cardiovascular benefits," said Dr. Subodh Verma, cardiac surgeon-scientist and director of the CardioLink platform at the Keenan Research Centre for Biomedical Science of St. Michael's.
"The reasons why this medication results in profound reductions in death and heart failure are largely unknown," added Dr. Verma, who led the EMPA-HEART CardioLink-6 trial. "And whether it can directly and favourably remodel the heart has been an important unanswered question."
EMPA-HEART is the first randomized, double-blind, parallel group study to investigate the effect of empagliflozin on the structure and function of the left ventricle in individuals with Type 2 diabetes and a history of cardiovascular disease, using MRI testing over a six-month period.
Increased thickness of the heart's left ventricle is associated with heart disease and heart failure. The study found that when the subjects were given empagliflozin, it caused a significant regression in left ventricular mass index.
The left ventricular mass index was assessed using cardiac MRI, the gold standard method for evaluating heart function.
The EMPA-HEART team included many physicians and scientists from St. Michael's, including Dr. Kim Connelly, Dr. Andrew Yan, Dr. David Mazer, Dr. David Fitchett, Dr. Peter Juni, director of the Applied Health Research Centre (AHRC), and Adrian Quan, research manager the CardioLink platform. It is the sixth CardioLink clinical trial.
The late-breaker sessions are used for presentations deemed too important to wait for the next AHA meeting.
"The results are truly impressive, since they were observed on top of excellent standard of care and seen within a very short period of time," said Dr. Connelly, one of the co-principal investigators of the EMPA-HEART study. Dr. Mazer added that the data "provide important clues as to how this medication is working, and how it may prevent heart failure in people with Type 2 diabetes."
Boehringer Ingelheim, a pharmaceutical company that manufactures empagliflozin, provided an unrestricted grant to conduct the EMPA-HEART study and the empagliflozin compound used in the study.
About St. Michael's Hospital
St. Michael's Hospital provides compassionate care to all who enter its doors. The hospital also provides outstanding medical education to future health care professionals in more than 29 academic disciplines.
Critical care and trauma, heart disease, neurosurgery, diabetes, cancer care, care of the homeless and global health are among the Hospital's recognized areas of expertise.
Through the Keenan Research Centre and the Li Ka Shing International Healthcare Education Centre, which make up the Li Ka Shing Knowledge Institute, research and education at St. Michael's Hospital are recognized and make an impact around the world. Founded in 1892, the hospital is fully affiliated with the University of Toronto.
St. Michael's Hospital with Providence Healthcare and St. Joseph's Health Centre now operate under one corporate entity.
United, the three organizations serve patients, residents and clients across the full spectrum of care, spanning primary care, secondary community care, tertiary and quaternary care services to post-acute through rehabilitation, palliative care and long-term care, while investing in world-class research and education.